Power Luke Thomas 4
4 · Caris Life Sciences, Inc. · Filed Dec 12, 2025
Insider Transaction Report
Form 4
Power Luke Thomas
See Remarks
Transactions
- Exercise/Conversion
Common Stock
2025-12-11$2.44/sh+24,750$60,390→ 124,321 total - Exercise/Conversion
Common Stock
2025-12-11$2.44/sh+37,500$91,500→ 161,821 total - Sale
Common Stock
2025-12-11$26.56/sh−60,850$1,616,444→ 100,971 total - Sale
Common Stock
2025-12-11$27.16/sh−1,400$38,018→ 99,571 total - Exercise/Conversion
Stock Option
2025-12-11−24,750→ 0 totalExercise: $2.44Exp: 2027-05-30→ Common Stock (24,750 underlying) - Exercise/Conversion
Stock Option
2025-12-11−37,500→ 0 totalExercise: $2.44Exp: 2028-11-14→ Common Stock (37,500 underlying)
Footnotes (4)
- [F1]The option exercises and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.11 to $27.07, inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.11 to $27.20, inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The stock option is fully vested and exercisable.